Jellyfish Protein Shows Potential as an Anti-Aging Dietary Supplement

By Joe Peters,2014-05-16 20:33
16 views 0
Jellyfish Protein Shows Potential as an Anti-Aging Dietary Supplement


    Jellyfish Protein Shows Potential to Help with Memory

Boston, Massachusetts (October 15, 2008)

    Quincy Bioscience (Madison, WI) announces that Prevagen? (, a dietary supplement consisting of the jellyfish protein apoaequorin, has displayed great potential to

    improve memory in healthy human subjects tested. The Prevagen Memory Study included 56

    participants that completed a 30 day open-label study (10 mg/day). The findings suggest that

    supplementation with apoaequorin, a well-known calcium-binding protein, might address the age-

    related deficits in memory that are often affiliated with decreasing calcium homeostasis.

    Quincy Bioscience has been researching the jellyfish protein for the past twelve years and has

    had Prevagen in the marketplace for just over one year. Their research showed that 57% of the

    participants experienced overall memory improvement in 30 days. 66% of participants reported

    better word recall in conversation within 30 days and many participants showed memory

    improvement in as few as 8 days. Participants ages averaged 56 years (20-78yrs.) and 66%

    were female and 34% male. All participants were in good health. There were no dropouts from

    the study due to side effects.

    “Too much calcium within a brain cell impairs its function and Prevagen works to regulate it.” says

    Underwood, co-founder of Quincy Bioscience. “Unfortunately, we lose our ability to regulate brain cell calcium as we age. At about forty, our brains produce fewer calcium-binding proteins. This

    causes calcium levels to rise throughout the nervous system. Neurons are flooded with

    dangerous levels of calcium and our brains slow down. We are excited to see these results.”

Apoaequorin, with its ability to bind to and lower calcium levels, can be used as a replacement

    for our own missing calcium-binding proteins and thereby slow age-related loss of cognitive

    function, memory, and alertness. Additional clinical trials are planned,” added Underwood, “but

    this is a great first step. It shows that we are on the right track to address age-related memory


The jellyfish protein is very similar to the calcium binding proteins found in the human nervous

    system which become depleted in age-related diseases like Alzheimer’s. Data demonstrating the neuroprotective ability of aequorin was first presented at the Society for Neuroscience meeting in


     “Having strong science is the key to helping people that are interested in natural and alternative

    health products,” added Mike Beaman, co-founder of Quincy Bioscience. “It is exciting that we can help the memory of others with Prevagen. There are many people that will benefit as the

    result of this important research.

    Quincy Bioscience will be exhibiting during the Natural Products ExpoEast at the Boston

    thConvention and Exhibition Center October 16-18th. Representatives will be on hand in booth #

    439 with literature and information detailing the research.

    # # #

    Quincy Bioscience ( is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization

    of novel compounds to fight the aging process. The company's products focus on restoring

    calcium balance related to neurodegenerative disorders and other destructive age-related

    mechanisms. Quincy Bioscience is developing health applications of the jellyfish protein

    apoaequorin for dietary supplement and pharmaceutical products. The company’s first product,

    Prevagen (, was launched in the fall of 2007 and is intended to supplement the loss of critical calcium-binding proteins depleted in the normal course of healthy aging.

    * These statements have not been evaluated by the FDA. This product is not intended to

    diagnose, treat, cure, or prevent any disease.

    For more information, contact Mark Underwood, President at or 414-303-0814.

Report this document

For any questions or suggestions please email